<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953755</url>
  </required_header>
  <id_info>
    <org_study_id>5/2018</org_study_id>
    <nct_id>NCT03953755</nct_id>
  </id_info>
  <brief_title>Surgery in Secondary Tricuspid Regurgitation</brief_title>
  <acronym>STRONG</acronym>
  <official_title>Surgery of Secondary Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, in cardiology/cardiosurgery the indicators for the surgical correction of&#xD;
      secondary tricuspid regurgitationare unclear. AIM: To compare right ventricle structural and&#xD;
      functional changes after operation in patients with secondary tricuspid regurgitation with&#xD;
      severe mitral /aortic valve pathology, requiring surgical intervention; define the factors&#xD;
      influencing major adverse cardiac events depending on the operation/non-operation due to&#xD;
      moderate tricuspid regurgitation. This study intends to include 200-300 people and will occur&#xD;
      over 5 years with an additional 3-year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background It has been demonstrated in recent large patient monitoring registers that the&#xD;
      presence of even mild secondary tricuspid regurgitation (TR) has a significant effect on life&#xD;
      expectancy. Currently, in cardiology/cardiosurgery the indicators for the surgical correction&#xD;
      of secondary TR are unclear. In this area, international guidelines lack randomized studies&#xD;
      and are based on a C level of evidence. C level evidence is based solely on the opinion of&#xD;
      experts, retrospective, and/or observational studies. The first indicator for tricuspid valve&#xD;
      (TV) surgery is considered to be a combination of TR with severe aortic or mitral valve&#xD;
      lesions that require surgical treatment. However, the level of indicators for moderate&#xD;
      corrections in such situations is typically II A-B. At the C level of evidence there is no&#xD;
      consensus for surgical treatment of such a defect in the international community. Severe TR&#xD;
      indicators are Class I while the evidence remains C level because it is not well established&#xD;
      that surgical treatment improves the prognosis of these patients. There is a lack of&#xD;
      information about the structural and functional changes of the right ventricle after surgery&#xD;
      depending on the degree of TR.&#xD;
&#xD;
      Aims and objectives of studying AIM: To compare right ventricle structural and functional&#xD;
      changes after operation in patients with secondary tricuspid regurgitation with severe mitral&#xD;
      /aortic valve pathology, requiring surgical intervention; define the factors influencing&#xD;
      major adverse cardiac events depending on the operation/non-operation due to moderate&#xD;
      tricuspid regurgitation.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
        1. To study tricuspid regurgitation parameters affecting the long-term prognosis for the&#xD;
           surgical correction of severe secondary tricuspid regurgitationof patients with severe&#xD;
           aortic/mitral valve pathology requiring surgical treatment.&#xD;
&#xD;
        2. To define hemodynamic parameters of patients with moderate tricuspid regurgitation, when&#xD;
           surgical treatment of this defect gives an additional improvement in the short-term and&#xD;
           long-term prognosis following surgical treatment of severe aortic/mitral valve diseases.&#xD;
&#xD;
        3. To study changes in contractility parameters in the right ventricle and tricuspid valve&#xD;
           function after reconstructive surgery over a period of 3 years.&#xD;
&#xD;
      Methods and study plans This study intends to include 200-300 people and will occur over 5&#xD;
      years with an additional 3-year follow-up.&#xD;
&#xD;
      Inclusion criterion: 1) Signed informed consent form, 2) Previously diagnosed aortic or&#xD;
      mitral heart diseases requiring surgical treatment, 3) Over 18 years of age 4) The presence&#xD;
      of moderate or severe secondary tricuspid insufficiency.&#xD;
&#xD;
      Exclusion criterion: 1) Significant oncology diseases with a known prognosis of a less than 1&#xD;
      year life expectancy.&#xD;
&#xD;
      Cardiologist examination and survey. Echocardiography All patients will undergo standard&#xD;
      echocardiography, including a detailed study of the function and sizes of the right ventricle&#xD;
      and right atrium, and measurement of global longitudinal left ventricular deformations using&#xD;
      the Speckle Tracking method, peak systolic and diastolic blood flow velocity in TV,&#xD;
      fractional changes in area, and tricuspid annulus systolic excursion. Tricuspid regurgitation&#xD;
      will be measured according to the standards of EAE/ASE, and will also use the recent 3-tiered&#xD;
      classification system of severe insufficiency.&#xD;
&#xD;
      Laboratory techniques Standard for surgical treatment of aortic/mitral valve Coronary&#xD;
      catheterization Standard for surgical treatment of aortic/mitral valve, Plan I. Initial visit&#xD;
      - cardiologist/cardiosurgeon clinical evaluation - survey and examination II.&#xD;
      Echocardiography study - screening - defining degree of tricuspid regurgitation III. Common&#xD;
      tests for surgical treatment of aortic/mitral valve IV. Patient randomization with only a&#xD;
      moderate degree of TR V. Surgical treatment VI. 30-40 days after surgery - cardiologist&#xD;
      examination VII. 90 days after surgery Â¬ - cardiologist examination + echocardiography VIII.&#xD;
      1 year after surgery - cardiologist examination + echocardiography IX. 3 years after surgery&#xD;
      - cardiologist examination + echocardiography Expected benefits for patients All patients&#xD;
      will receive advanced tests using the latest safe ultrasound methods. Frequent&#xD;
      echocardiography and patient observations can reveal possible complications after cardiac&#xD;
      surgery for aortic/mitral diseases; This study will allow for the correction of drug therapy&#xD;
      due to extended diagnosis.&#xD;
&#xD;
      Severe lesions of the tricuspid valve and aortic / mitral heart defects will be corrected in&#xD;
      all patients.&#xD;
&#xD;
      New and / or untested methods of treatment will not be used in this study. All surgical&#xD;
      procedures will already have undergone testing and been proven effective for the treatment of&#xD;
      heart diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in end-diastolic dimension</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>Difference in end-diastolic dimension of right ventricle between of pre- and post- operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in tricuspid annular plane systolic excursion</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>Difference in TAPSE between of pre- and post- operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in right atrium volume index</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>Difference in right atrium volume index between of pre- and post- operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in fraction of area contraction of right ventricle</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>Difference in fraction of area contraction between pre- and post- operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in right ventricle global strain rate</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>Difference in right ventricle global strain rate between of pre- and post- operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tricuspid regurgitant volume</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>tricuspid regurgitant volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vtricuspid effective regurgitant oriface</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>tricuspid effective regurgitant oriface</description>
  </primary_outcome>
  <primary_outcome>
    <measure>square of tricuspid regurgitation</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>square of tricuspid regurgitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>death, myocardial infarction, new hospital readmission, heart transplant, ventricular assist device implantation, aborted sudden death, pulmonary oedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of all-cause death</measure>
    <time_frame>3 month, 1 year, 3 year</time_frame>
    <description>all-cause death</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Control 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no/mild tricuspid regurgitation - left-side surgery alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate TR - left-side surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>moderate tricuspid regurgitation - left-side surgery alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate TR - left-side surgery+TVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moderate tricuspid regurgitation - left-side surgery+tricuspid valve surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>tricuspid regurgitation - left-side surgery +tricuspid valve surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tricuspid valve repair</intervention_name>
    <description>Tricuspid valve repair</description>
    <arm_group_label>moderate TR - left-side surgery+TVS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Indication left-side valve surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwillingness to give informed consent and to enter a regular follow-up program.&#xD;
&#xD;
          2. Prior surgical or percutaneous mitral valve intervention&#xD;
&#xD;
          3. Contraindication to cardiopulmonary bypass (CPB)&#xD;
&#xD;
          4. Clinical signs of cardiogenic shock at the time of randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitry Shmatov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Petersburg State University, Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Zagatina, MD, PhD</last_name>
    <phone>+79213297087</phone>
    <email>zag_angel@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dmitry Shmatov, MD, PhD</last_name>
    <phone>+79110833115</phone>
    <email>dv.shmatov@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Petersburg State University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Zagatina, MD, PhD</last_name>
      <phone>+79213297087</phone>
      <email>zag_angel@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Zagatina Angela</investigator_full_name>
    <investigator_title>Head of cardiology department</investigator_title>
  </responsible_party>
  <keyword>tricuspid regurgitation</keyword>
  <keyword>tricuspid surgery</keyword>
  <keyword>moderate tricispid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 year</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03953755/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

